Britain's Terry Smith made public for the first time on Thursday why his fund dumped its Diageo stake last year, citing problems with its new management and early signs that weight loss drugs threatened the drinks sector.

Researchers from Canada reviewed the results of 26 trials to determine which of the weight loss jabs are the most effective for obese adults who do not have diabetes.

According to that study, those who use GLP-1 dugs, such as Wegovy and Ozempic, cut their grocery spend by about 6% during the first few months after starting their prescription, translating to $416 annually. The impact is even greater in higher-income households earning over $125,000, who reduce their grocery spending by 9%, or $690, annually.

For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious for weight loss, according to a review published online Jan. 7 in the Annals of Internal Medicine.